Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cross-resistance and drug sequence in prostate cancer

19 Mar 2021

Abstract excerpt

The treatment landscape of advanced prostate cancer has widely expanded over the past years with androgen receptor signaling inhibitors (ARSIs) and taxane chemotherapy moving to earlier disease stages in the treatment of prostate cancer. With the increasing use of ARSIs in earlier disease stages, cross-resistance between treatments has emerged, which is a dominant impediment in current clinical practice. To...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Lipids, and Metabolism
Share to Prostate Cancer Diagnosis and Treatment
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33799049
DOI: 10.1016/j.drup.2021.100761

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cross-resistance and drug sequence in prostate cancerPMID 33799049Read ↗

Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate CancerSemantic proximity Read ↗

Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate CancerSemantic proximity Read ↗

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approachesSemantic proximity Read ↗

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanismsSemantic proximity Read ↗

Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistanceSemantic proximity Read ↗

Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate CancerSemantic proximity Read ↗

Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer.Semantic proximity Read ↗

Molecular mechanisms of docetaxel resistance in prostate cancerSemantic proximity Read ↗

Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategiesSemantic proximity Read ↗

Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancerSemantic proximity Read ↗

KIF14 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer by promoting AKT phosphorylationSemantic proximity Read ↗

Targeting the androgen receptor and overcoming resistance in prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.